Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabergoline and Gliclazide in T2DM
NCT03313661Phase 3Unknown
- Start
- Oct 2017
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cabergoline in type 2 diabetes mellitus (T2DM). Status: unknown.
02
Drugs
cabergoline
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03313661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03313661.